Your browser doesn't support javascript.
loading
Benzopyran sulfonamides as KV1.5 potassium channel blockers.
Lloyd, John; Atwal, Karnail S; Finlay, Heather J; Nyman, Michael; Huynh, Tram; Bhandaru, Rao; Kover, Alexander; Schmidt, Joan; Vaccaro, Wayne; Conder, Mary Lee; Jenkins-West, Tonya; Levesque, Paul.
Affiliation
  • Lloyd J; Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 5400, Princeton, NJ 08543-5400, USA. john.lloyd@bms.com
Bioorg Med Chem Lett ; 17(12): 3271-5, 2007 Jun 15.
Article in En | MEDLINE | ID: mdl-17462888
K(V)1.5 blockers have the potential to be atrium-selective agents for treatment of atrial fibrillation. The benzopyrans provide a template for the synthesis of potent and selective K(V)1.5 blockers.
Subject(s)
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Atrial Fibrillation / Sulfonamides / Benzopyrans / Atrial Function / Potassium Channel Blockers / Kv1.5 Potassium Channel Language: En Journal: Bioorg Med Chem Lett Journal subject: BIOQUIMICA / QUIMICA Year: 2007 Document type: Article Affiliation country: United States Country of publication: United kingdom
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Atrial Fibrillation / Sulfonamides / Benzopyrans / Atrial Function / Potassium Channel Blockers / Kv1.5 Potassium Channel Language: En Journal: Bioorg Med Chem Lett Journal subject: BIOQUIMICA / QUIMICA Year: 2007 Document type: Article Affiliation country: United States Country of publication: United kingdom